IL-33 promotes the migration and proliferation of circulating fibrocytes from patients with allergen-exacerbated asthma

Biochemical and Biophysical Research Communications

Volumn 426, Issue 1, 2012, Pages 116-121

  Bianchetti, Lorenza ^a,b   Marini, Maurizio A ^c   Isgrò, Mirko ^a,b   Bellini, Alberto ^a   Schmidt, Matthias ^a   Mattoli, Sabrina ^a  

^a Avail Biomedical Research Institute   (Switzerland)

^b Laboratory of Cytopathology and Cytogenetics   (Italy)

^c Multispecialty Outpatient Clinic and Diagnostic Center   (Italy)

Author keywords

Allergy; Asthma; Cell migration; Cell proliferation; Fibrocytes; Interleukin 33

Indexed keywords

COLLAGEN TYPE 1; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; MESSENGER RNA; RECOMBINANT CYTOKINE; RECOMBINANT PROTEIN;

AIRWAY; ALLERGIC ASTHMA; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CIRCULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE EXACERBATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALLERGENS; ASTHMA; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; INTERLEUKINS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS;

EID: 84866333201     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.047     Document Type: Article

References (37)

1. Bucala R., Spiegel L.A., Chesney J., et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994, 1:71-81.
2. Chesney J., Metz C., Stavitsky A.B., et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 1998, 160:419-425.
3. Abe R., Donnelly S.C., Peng T., et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 2001, 166:7556-7562.
4. Mattoli S., Bellini A., Schmidt M. The role of a human hematopoietic mesenchymal progenitor in wound healing and fibrotic diseases and implication for therapy. Curr. Stem Cell Res. Ther. 2009, 4:266-280.
5. Schmidt M., Sun G., Stacey M.A., et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 2003, 171:380-389.
6. Nihlberg K., Larsen K., Hultgårdh-Nilsson A., et al. Tissue fibrocytes in patients with mild asthma: a possible link to thickness of reticular basement membrane?. Respir. Res. 2006, 7:50.
7. Wang C.-H., Huang C.-D., Lin H.-C., et al. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am. J. Respir. Crit. Care Med. 2008, 178:583-591.
8. Saunders R., Siddiqui S., Kaur D., et al. Fibrocyte localization to the airway smooth muscle is a feature of asthma. J. Allergy Clin. Immunol. 2009, 123:376-384.
9. Bellini A., Marini M.A., Bianchetti L., et al. Interleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunol. 2012, 5:140-149.
10. Durrani S.R., Viswanathan R.K., Busse W.W. What effect does asthma treatment have on airway remodeling? Current perspectives. J. Allergy Clin. Immunol. 2011, 128:439-448.
11. Borish L., Steinke J.W. Interleukin-33 in asthma: how big of a role does it play?. Curr. Allergy Asthma Rep. 2011, 11:7-11.
12. Oboki K., Nakae S., Matsumoto K., Saito H. IL-33 and airway inflammation. Allergy Asthma Immunol. Res. 2011, 3:81-88.
13. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
14. Carriere V., Roussel L., Ortega N., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 2007, 104:282-287.
15. Roussel L., Erard M., Cayrol C., Girard J.P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008, 9:1006-1012.
16. Cayrol C., Girard J.-P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 2009, 106:9021-9026.
17. Ali S., Mohs A., Thomas M., et al. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J. Immunol. 2011, 187:1609-1616.
18. Ohno T., Oboki K., Kajiwara N., et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 2009, 183:7980-7987.
19. Talabot-Ayer D., Lamacchia C., Gabay C., Palmer G. Interleukin-33 is biologically active independently by caspase-1 cleavage. J. Biol. Chem. 2009, 284:19420-19426.
20. Kakkar R., Hei H., Dobner S., Lee R.T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 2012, 287:6941-6948.
21. Ali S., Huber M., Kollewe C., et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl. Acad. Sci. USA 2007, 104:18660-18665.
22. Chackerian A.A., Oldham E.R., Murphy E.E., et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 2007, 179:2551-2555.
23. Nishida A., Andoh A., Imaeda H., et al. Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 2010, 59:531-541.
24. Rankin A.L., Mumm J.B., Murphy E., et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J. Immunol. 2010, 184:1526-1535.
25. Global Initiative for Asthma (GINA), Global strategy for asthma management and prevention. Updated 2010, Available at: (accessed 07.02.11). http://www.ginasthma.com.
26. Reddel H.K., Taylor D.R., Bateman E.D., et al. An official America Thoracic Society/European Respiratory Society statement: asthma control and exacerbations. Standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009, 180:59-99.
27. Pastorelli L., Garg R.R., Hoang S.B., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. USA 2010, 107:8017-8022.
28. Komai-Koma M., Xu D., Li Y., et al. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 2007, 37:2779-2786.
29. Glück J., Rymarczyk B., Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm. Res. 2012, 61:547-550.
30. Préfontaine D., Nadigel J., Chouiali F., et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 2010, 125:752-754.
31. Verri W.A., Souto F.O., Vieira S.M., et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 2010, 69:1697-1703.
32. Neill D.R., Wong S.H., Bellosi A., et al. Nuocytes represent a new innate effector leukocyte that mediates type 2 immunity. Nature 2010, 464:1367-1370.
33. Yasuoka S., Kawanokuchi J., Parajuli B., et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011, 1385:8-17.
34. Manetti M., Ibba-Manneschi L., Liakouli V., et al. The IL-1-like cytokine IL-33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann. Rheum. Dis. 2010, 69:598-605.
35. Yanaba K., Yoshizaki A., Asano Y. a Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin. Rheumatol. 2011, 30:825-830.
36. Mathai S.K., Gulati M., Peng X., et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 2010, 90:812-823.
37. Tourkina E., Bonner M., Oates J., et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011, 4:15.